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SOCS1 Is a Critical Inhibitor of Interferon g
Signaling and Prevents the Potentially Fatal
Neonatal Actions of this Cytokine
presentation, activation of macrophages, antiviral, and
antiproliferative responses (reviewed by Tatake and
Zeff, 1993; Boehm et al., 1997).
The major signal transduction pathway initiated by
interferons has been elucidated by a series of elegant
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main of a second STAT1 molecule, mediating dimeriza-
tion (Shuai et al., 1994). STAT1 dimers subsequentlyMice lacking suppressor of cytokine signaling-1 (SOCS1)
migrate to the nucleus, where they bind to gamma-acti-develop a complex fatal neonatal disease. In this study,
vated sequence (GAS) elements contained within theSOCS12/2 mice were shown to exhibit excessive re-
promoters of IFNg-inducible genes (Shuai et al., 1992;sponses typical of those induced by interferon g (IFNg),
Muller et al., 1993b), including the genes for induciblewere hyperresponsive to viral infection, and yielded
nitric oxide synthase (iNOS) and the transcription factormacrophages with an enhanced IFNg-dependent ca-
interferon regulatory factor 1 (IRF1). The increased sus-pacity to kill L. major parasites. The complex disease
ceptibility to Mycobacteria, Leishmania major, andin SOCS12/2 mice was prevented by administration of
some viruses in mice or humans harboring mutations inanti-IFNg antibodies and did not occur in SOCS12/2
the genes for IFNg, its receptor, IRF1, or iNOS highlightsmice also lacking the IFNg gene. Although IFNg is
the importance of this pathway in resistance to infectionessential for resistance to a variety of infections, the
(Huang et al., 1993; Matsuyama et al., 1993; Kamijo etpotential toxic action of IFNg, particularly in neonatal
al., 1994; MacMicking et al., 1995; Durbin et al., 1996;mice, appears to require regulation. Our data indicate
Meraz et al., 1996; Newport et al., 1996; Lu et al., 1998).that SOCS1 is a key modulator of IFNg action, allowing
The actions of IFNg are not always beneficial, sincethe protective effects of this cytokine to occur without
infections may elicit a host response of sufficient magni-the risk of associated pathological responses.
tude to become life threatening, for example, morbidity
associated with Staphylococcus aureus infection andIntroduction
the hepatotoxicity associated with hepatitis B infection
(Billiau and Vandekerckhove, 1991; Ando et al., 1993;Resistance to infections is dependent on the coordi-
Matthys et al., 1995). The potentially toxic effects ofnated action of the cytokine network. Key contributions
IFNg, including fatty degeneration of the liver, have alsoare made by interferons (IFN; Billiau, 1996; Boehm et
been demonstrated in experiments in which circulatingal., 1997; De Maeyer and De Maeyer-Guignard, 1998),
IFNg levels are experimentally elevated in neonatal micewhich comprise two broad groups. Type I interferons
(Gresser, 1982; Toyonaga et al., 1994). Regulatory mech-include the closely related forms of IFNa and a single
anisms must therefore exist to maintain the fine balanceform of IFNb, whereas IFNg is the sole type II interferon
between beneficial and detrimental responses to IFNg.(De Maeyer and De Maeyer-Guignard, 1998). The IFNa
This is achieved in part through the production of in-proteins and IFNb are produced by many cell types in
terleukin-4 (IL-4), IL-10, and IL-13, which counteract theresponse to viral infection (De Maeyer and De Maeyer-
effects of IFNg (Paul, 1991; Moore et al., 1993; ZurawskiGuignard, 1998). In contrast, IFNg is produced exclu-
and de Vries, 1994), and by negative regulation of IFNgsively by activated T cells and natural killer (NK) cells
signal transduction, for example, by the SH2 domain±(Billiau, 1996; Boehm et al., 1997; De Maeyer and De
containing phosphatase SHP1 (Massa and Wu, 1996).Maeyer-Guignard, 1998). IFNg serves to upregulate ex-
In vitro studies have also implicated a family of SH2-pression of a wide variety of genes involved in antigen
containing proteins, the suppressors of cytokine signal-
ing (SOCS) proteins, in the negative regulation of cyto-§ To whom correspondence should be addressed (e-mail: hilton@
kine signal transduction. Of the eight SOCS proteinswehi.edu.au).
‖ These authors contributed equally to this work. (SOCS1 to 7 and CIS), SOCS1 and SOCS3 appear to be
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the most potent inhibitors of cytokine signaling (Nichol- IFNg signal transduction, was readily detected in the
son et al., 1999). SOCS1 was initially identified in a func- livers of 14-day-old SOCS12/2 mice but not SOCS11/2
tional screen for proteins capable of inhibiting IL-6 sig- or wild-type mice (Figure 1A). We found, however, no
naling (Starr et al., 1997). Subsequent studies have evidence of STAT3 activation (Figure 1A; data not
shown that STAT activation in response to many cyto- shown), suggesting that dysregulated signaling medi-
kines results in increased transcription of the SOCS1 ated by other inflammatory cytokines such as leukemia
and SOCS3 genes and that, when overexpressed, inhibitory factor (LIF), IL-6, and oncostatin M (OSM) that
SOCS1 and SOCS3 inhibit the biological effect of cyto- utilize STAT3 was not occurring in SOCS12/2 animals.
kines, including IFNg, that act through the JAK/STAT In addition, expression of mRNA for the IFNg-induc-
pathway (Wang et al., 1996; Endo et al., 1997; Matsu- ible genes IRF1 and iNOS was elevated in tissues of
moto et al., 1997; Naka et al., 1997; Starr et al., 1997; SOCS12/2 mice (Figure 1B). Likewise, class I MHC ex-
Adams et al., 1998; Auernhammer et al., 1998; Bjorbaek pression was markedly elevated in the liver (Figure 1C)
et al., 1998; Hilton et al., 1998; Sakamoto et al., 1998; and in hematopoietic cells, including thymic and splenic
Song and Shuai, 1998; Ito et al., 1999). Consistent with T cells, bone marrow and splenic B cells, and monocytes
the observation that SOCS1 can inhibit the action of a of SOCS12/2 mice (Figure 1D and data not shown). Ele-
broad range of cytokines, SOCS1 appears to bind to all vation of class I MHC expression in the thymus, bone
four members of the JAK family and inhibit their catalytic marrow, and spleen cells was observed at birth, prior
activity (Endo et al., 1997; Naka et al., 1997; Nicholson to the development of overt disease.
et al., 1999). These studies have led to the view that
SOCS1 may be part of a general negative feedback loop IFNg Is Essential for Disease Development
regulating cytokine action. and Premature Death in Neonatal
The importance of this regulatory pathway was revealed SOCS12/2 Mice
in mice lacking a functional SOCS1 gene (SOCS12/2 To directly assess the role of IFNg in the onset and
mice). These mice die between 2 and 3 weeks of age development of disease in SOCS12/2 mice, three litters
of a disease that involves fatty degeneration and necro- of mice (29 in total) from SOCS11/2 parents were injected
sis of the liver, macrophage infiltration of several organs, twice weekly from birth with a neutralizing anti-IFNg
and multiple hematopoietic abnormalities, including se- antibody. Only one death occurred (at day 1, of a
vere lymphopenia (Starr et al., 1998; Metcalf et al., 1999). SOCS11/2 mouse), while the remaining 28 mice re-
In this report, we establish that SOCS12/2 mice are hy- mained in good health and were of normal body weight
persensitive to IFNg and that the complex multiorgan when analyzed at 3 weeks of age (Table 1). Genotyping
disease and premature death that develops in these subsequently revealed that six of these mice were ho-
mice can be prevented by administration of neutralizing mozygous SOCS1 mutants, indicating that IFNg was
anti-IFNg antibodies and is absent in mice lacking both absolutely required for the premature death of SOCS12/2
functional SOCS1 and IFNg genes. We conclude that mice (Figures 2A and 2B).
SOCS1 is a critical regulator of cellular sensitivity to
At 21 days, anti-IFNg-treated SOCS12/2 mice were
interferon-g, balancing the beneficial immunological ac-
compared with moribund 12- to 21-day-old SOCS12/2
tivities with the fatal neonatal effects of this cytokine.
mice and 12- to 21-day-old SOCS11/1 and SOCS11/2
mice. Untreated SOCS12/2 mice showed a uniform se-Results
ries of pathological changes (Figure 3; Tables 1 and 2),
including fatty degeneration and necrosis of liver cells,Aberrant IFNg Signaling in SOCS12/2 Mice
infiltration of the liver, lungs, pancreas, heart, and skinThe capacity of SOCS1 to inhibit IFNg signaling in vitro
with macrophages, and thickening of the skin epithelium(Starr et al., 1997; Sakamoto et al., 1998; Song and Shuai,
with keratinization. Untreated SOCS12/2 mice also ex-1998) and the observation that administration of this
hibited profound alterations in hematopoiesis and lym-cytokine to neonatal mice induces pathology similar to
phopoiesis with atrophy of the thymic cortex, failure ofthat observed in SOCS12/2 mice (Gresser et al., 1981)
lymphoid follicle development in the spleen, and bonesuggested that the SOCS1-deficient disease may be
marrow lymphopenia (Figures 4A and 4B; Tables 1 andmediated by IFNg. To directly compare the effects of
2). Remarkably, most organs from anti-IFNg antibody±IFNg administration with SOCS12/2 pathology, neonatal
treated SOCS12/2 mice were normal, the exceptionsC57BL/6 mice were injected daily for 14 days with 3 mg
being minor cuffing of lung vessels and persistence ofof IFNg. Like SOCS12/2 mice, the injected mice died
erythropoiesis in the spleen (Figure 3; Tables 1 and 2).in the second and third weeks of life, and histological
Similarly, hematopoietic abnormalities, including lym-examination showed that in addition to hepatic changes,
phopenia, were also reduced, although not entirely elimi-their lungs, heart, and pancreas were infiltrated with
nated (Figure 4; Tables 1 and 2). Protection from diseasemacrophages. Moreover, the hematopoietic abnormali-
was specifically associated with inhibition of IFNg be-ties observed, including severe lymphopenia and mod-
cause injection of SOCS12/2 mice with either anti-IL-6erate granulocytosis, were also similar to those seen in
or control rat immunoglobulin did not alter the kineticsSOCS12/2 mice (data not shown).
of onset or typical multiorgan nature of the disease (Fig-To determine more directly whether IFNg plays a role
ure 2B).in the development of pathology in SOCS12/2 mice, we
Because treatment of SOCS12/2 mice with anti-IFNgexamined them for the presence of a dysregulated signal
antibody did not entirely eliminate disease, we wishedtransduction response to IFNg. Using an oligonucleotide
to determine whether the residual pathology was dueprobe capable of binding to STAT1 and STAT3 in electro-
mobility shift assays, activation of STAT1, a key step in to the involvement of other cytokines or to the inefficient
SOCS1 Is a Key Regulator of IFNg Signaling
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Figure 1. Experimentally Unmanipulated SOCS12/2 Mice Show Evidence of an Ongoing Response to IFNg
(A) EMSA of extracts of livers from SOCS11/2 mice injected with 2 mg of IFNg or untreated SOCS11/1 and SOCS12/2 mice. Prior to DNA
binding, samples were treated, as indicated, with antibodies to either STAT1 or STAT3.
(B) Northern blot analyses showing mRNA from brain (b), kidney (k), liver (li), lung (lu), spleen (s), and thymus (t) from SOCS11/1 and SOCS12/2
mice hybridized with an iNOS probe (upper panel), IRF1 probe (central panel), or GAPDH probe (lower panel).
(C) Immunohistochemistry showing class I MHC expression in the liver. Liver sections were stained with anti-class I MHC antibody or isotype
control antibody and a peroxidase-labeled secondary antibody. Sections were counterstained with Giemsa.
(D) FACS analysis of class I MHC and Mac1 expression on bone marrow cells from SOCS11/1 and SOCS12/2 mice. Cells were stained with
a biotinylated anti-class I MHC antibody and streptavidin-phycoerythrin followed by an FITC-conjugated anti-Mac1 antibody and were analyzed
by flow cytometry. Data shown are representative of at least three independent experiments.
neutralization of IFNg. To distinguish between these males and females have proven fertile. Interestingly, 8
out of 12 SOCS12/2 IFNg1/2 mice became moribundpossibilities, we interbred SOCS11/2 and IFNg2/2 mice
to yield animals lacking both SOCS1 and IFNg. As previ- between 2 and 12 weeks of age (Figure 2D), while the
remaining 4 mice were alive after 15 weeks and wereous studies of IFNg2/2 mice have reported no postnatal
death (Dalton et al., 1993), it was not surprising to ob- fertile and healthy.
Together, these data from IFNg antibody treatmentserve that all SOCS11/1 and SOCS11/2 mice remained
healthy irrespective of their IFNg genotype (data not and intercrosses with IFNg2/2 mice indicate that the full
spectrum of disease that results in the postnatal deathshown). All SOCS12/2 IFNg1/1 mice died or became mor-
ibund in the second and third weeks of life (Figure 2D), of SOCS12/2 mice is dependent on the action of IFNg.
and their disease was identical to that of unmanipulated
SOCS12/2 mice (Figures 3 and 4; Tables 1 and 2). Con- SOCS1 Deficiency Results in
IFNg Hyperresponsivenesssistent with the antibody administration studies, all
SOCS12/2 IFNg2/2 mice survived normally to weaning The disease in SOCS12/2 mice could reflect either an
intrinsic cellular hypersensitivity to IFNg and/or the pro-age and appeared overtly healthy (Figure 2D). A detailed
analysis of 12 SOCS12/2 IFNg2/2 mice at 3 weeks of duction of elevated amounts of the cytokine. In this
regard, SOCS12/2 granulocyte-macrophage progenitorage revealed normal body and organ weight and no
hematological abnormalities (Figure 4D and Table 1). cells have been shown to be hypersusceptible to inhibi-
tion by IFNg (Metcalf et al., 1999). To further investigateOnly 2 of 12 mice showed lymphoid cuffing of lung ves-
sels, and 8 of 12 mice had thymi with an enlarged me- these possibilities, the capacity of macrophages grown
from bone marrow of wild-type or SOCS12/2 mice todulla but normal cortex (Table 2), neither of which were
histological features of the typical SOCS12/2 disease. kill the intracellular parasite Leishmania major following
IFNg stimulation was determined. Macrophages wereSOCS12/2 IFNg2/2 mice, some of which are now over 6
months old, have remained uniformly healthy, and both infected 6 hr after stimulation with various doses of IFNg
Cell
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effector involved in the intracellular killing of L. major
(data not shown).
The hyperresponsiveness of cells from SOCS12/2
mice to IFNg in vitro was paralleled by an increased
resistance of SOCS12/2 mice to viral infection in vivo.
When 5-day-old mice were infected with Semliki forest
virus, all SOCS11/1 and SOCS11/2 mice died within 2 to
3 days. However, SOCS12/2 mice largely survived this
early postinfection period and only became ill 3 to 21
days after viral challenge (Figure 5B). This suggests an
almost complete resistance to infection, because the
survival pattern of infected and uninfected SOCS12/2
mice was similar.
IFNg levels in the serum and in media conditioned by
organs taken from SOCS12/2 or control littermate mice
were investigated using ELISA and/or antiviral assays.
At a limit of detection of 3 U/ml, we were unable to
detect IFNg in serum of mice of either genotype, and
media conditioned by organs from SOCS12/2 mice did
not reproducibly contain more IFNg than those from
their wild-type littermates.
Neonatal Death of SOCS12/2 Mice Occurs
under Germ-Free Conditions
Because IFNg was clearly central to the development
of disease in SOCS12/2 mice, we were interested to
determine whether subclinical infection in conventional
mice might induce increased production of IFNg and
precipitate the early neonatal death of SOCS12/2 mice.
Three litters of pups produced from the mating of
SOCS11/2 mice were delivered by cesarean section into
Figure 2. Development of Disease in SOCS12/2 Mice Is Dependent a strictly germ-free environment. As expected, SOCS11/1
on IFNg and Occurs in a Germ-Free Environment and SOCS11/2 pups were among the progeny, and these
(A) Rapid onset of morbidity of untreated SOCS12/2 but not were weaned normally and as adults exhibited enlarged
SOCS11/1 or SOCS11/2 mice.
ceca characteristic of mice in a germ-free environment.(B) Twice weekly injection of neonatal SOCS12/2 mice with anti-
In contrast, germ-free SOCS12/2 pups died during theIFNg but not anti-IL-6 or control antibody prevents morbidity.
second and third weeks of life, the same age at which(C) Rapid onset of morbidity in SOCS12/2 but not SOCS11/1 or
SOCS11/2 mice born and reared in a germ-free environment. conventional SOCS12/2 mice die (Figure 2C). Analyses
(D) Prevention of morbidity in SOCS12/2 IFNg2/2 mice and ameliora- of seven of these moribund germ-free SOCS12/2 mice
tion of morbidity in SOCS12/2 IFNg1/2 mice in comparison with revealed that their organ pathology and peripheral blood
SOCS12/2 IFNg1/1 mice. Seventeen SOCS12/2 IFNg2/2 mice have
abnormalities were identical to SOCS12/2 mice raisedbeen examined to date, with twelve animals being sacrificed for
under conventional conditions.detailed histological and hematological analysis at 3 weeks of age
and the remaining five being left for long-term observation.
Discussion
SOCS1 Is a Critical Regulator of IFNg-Mediatedin the presence of 100 ng/ml lipopolysaccharide. After
2 hr at all IFNg concentrations, 30% to 50% of macro- Signal Transduction
SOCS1 is indispensable for survival beyond the postna-phages from both SOCS11/1 and SOCS12/2 mice were
infected, and this percentage persisted for up to 48 hr tal period. Mice lacking this regulator die before weaning
from a complex disease characterized by fatty degener-in macrophages of both genotypes in the absence of
cytokine (Figure 5A). The ability of IFNg activation to ation of the liver, macrophage infiltration of several or-
gans, and severe lymphopenia (Starr et al., 1998). Weenhance macrophage killing of L. major was demonstra-
ble, because only 1% to 3% of cells from both SOCS11/1 demonstrate here that this fatal syndrome is associated
with the specific activation of STAT1 and elevated ex-and SOCS12/2 mice were still infected with live para-
sites 48 hr after treatment with 10 U/ml of IFNg (Figure pression of IRF1, iNOS, and class I MHC, strongly im-
plying that IFNg signaling pathways are aberrantly active5A). Strikingly, although #0.1 U/ml IFNg had little or no
effect on killing by SOCS11/1 macrophages, cells from in vivo in the absence of SOCS1. Remarkably, all organ
pathology was eliminated or markedly reduced, andSOCS12/2 mice maintained efficient killing when stimu-
lated with as little as 0.01 U/ml IFNg (Figure 5A), thus death was prevented by treatment of neonatal SOCS12/2
mice with a neutralizing anti-IFNg antibody. The amelio-exhibiting at least 100-fold increased sensitivity to IFNg.
The hypersensitivity of macrophages from SOCS12/2 ration of disease was specific to the inhibition of IFNg
because treatment of SOCS12/2 mice with neutralizingmice to IFNg was confirmed by the demonstration of an
increased capacity to produce nitric oxide, the major anti-IL-6 antibodies or control immunoglobulin had no
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Figure 3. Prevention of Tissue Pathology in
SOCS12/2 Mice by Treatment with Anti-IFNg
Antibody
Neonatal SOCS12/2 mice were treated twice
weekly with either anti-IFNg antibody or con-
trol antibody. Anti-IFNg antibody±treated
mice were healthy at 21 days of age and were
sacrificed. Control antibody±treated mice de-
veloped disease between 9 and 16 days of
age and were sacrificed when moribund. The
normal histological appearance of organs
from anti-IFNg antibody-treated SOCS12/2
mice (right-hand panels) is contrasted with
the atrophy of the cortex of the thymus, the
fatty degeneration, hematopoietic infiltration
and necrosis of the liver, macrophage accu-
mulation around the bronchi and in the alveo-
lar walls in the lung, and macrophage infiltra-
tion and acinar tissue destruction of the
pancreas observed in SOCS12/2 mice treated
with control antibody (left-hand panels).
protective effect. We were also unable to find any evi- also displayed no consistent differences in IFNg concen-
trations. Finally, while SOCS12/2 IFNg2/2 mice have re-dence of dysregulated activation of STAT3 in SOCS12/2
mice, the STAT protein used preferentially by inflamma- mained disease free, some SOCS12/2 IFNg1/2 mice do
die with a more slowly developing disease. The delayedtory cytokines such as IL-6 and LIF (Ihle et al., 1994). In
addition, the full spectrum of disease development was disease in mice containing only a single functional IFNg
allele suggests that IFNg concentrations may be limitingcompletely prevented in mice genetically deficient in
IFNg as well as SOCS1, and a delayed disease devel- in these mice and therefore unlikely to be grossly ele-
vated in SOCS12/2 mice. IFNg is thought to be usuallyoped in SOCS12/2 mice that had only a single functional
copy of the IFNg gene. The absence of SOCS1 corre- produced by T cells and NK cells in response to infec-
tion. Since SOCS12/2 mice succumb to disease inlated with marked in vitro hypersensitivity to IFNg in
macrophages infected with the intracellular parasite L. strictly germ-free conditions, the IFNg required for dis-
ease development in SOCS12/2 mice might either repre-major. Hypersensitivity to IFNg was also observed when
nitric oxide (NO) production was measured following sent basal production or be produced aberrantly. While
our studies have clearly demonstrated an indispensablestimulation of macrophages with LPS and IFNg. Like-
wise, hematopoietic cells from SOCS12/2 mice have also role for IFNg in the multiorgan pathology of SOCS12/2
mice, the source of this cytokine and the identity ofbeen found to be more susceptible to inhibition of prolif-
eration by IFNg but normally responsive to most hemato- potential downstream effectors of IFNg action remain
to be examined.poietic cytokines that also act through the JAK/STAT
pathway (Metcalf et al., 1999). Together these data
clearly establish that SOCS1 is an essential physiologi-
cal regulator of cellular sensitivity to IFNg signaling. Specificity of SOCS1 Action In Vivo
Previous in vitro data suggested that SOCS1 can directlyOur results do not exclude the possibility that an ele-
vated production of IFNg in SOCS12/2 mice might con- interact with all four members of the JAK family, resulting
in the inhibition of their catalytic activity (Endo et al.,tribute to disease development. However, within the sensi-
tivity of the assays used, as in normal animals, we were 1997; Naka et al., 1997). Consistent with this range of
action, overexpression of SOCS1 in cell lines inhibitedunable to detect IFNg in the circulation of SOCS12/2 mice.
Media conditioned by organs of SOCS12/2 or normal mice signal transduction from a large number of cytokines,
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a lethal hyperresponsiveness to IFNg, abnormal re-
sponses to other cytokines may not be manifested so
dramatically. Our studies to date suggest that responses
to most hematopoietic cytokines are not altered in
SOCS12/2 mice (Metcalf et al., 1999). However, the post-
natal lethality in mice lacking this protein has prevented
analysis of signaling by these or other cytokines in the
adult mouse. Clearly, the availability of healthy SOCS12/2
IFNg2/2 mice will now allow the full spectrum of in vivo
SOCS1 activity to be definitively resolved.
Binding of IFNg to its cell surface receptor triggers
the activation of JAK1 and JAK2. While in vitro studies
have shown SOCS1 is able to inhibit the function of both
these kinases, the biochemical specificity of SOCS1 ac-
tion in vivo remains to be determined. The inhibition of
JAK activity by SOCS1 may regulate IFNg signaling in
several ways, for example, by determining the threshold
concentration of IFNg capable of triggering a biological
response or by regulating the magnitude or length of a
response to a particular concentration of IFNg. Distin-
guishing between these possibilities will require a care-
ful comparison of the capacity of different doses of IFNg
Figure 4. Prevention of B Lymphopenia in SOCS12/2 Mice by Treat- to induce JAK1 and JAK2 activation, IFNg receptor
ment with Anti-IFNg Antibody or Generation of SOCS12/2 IFNg2/2 phosphorylation, STAT1 activation, and expression of
Mice STAT1-regulated genes in wild-type and SOCS1-defi-
Spleen cells were collected from (A) wild-type mice, (B) SOCS12/2 cient cells.
mice treated with a control antibody, (C) SOCS12/2 mice treated
As SOCS1 is a member of a larger family of relatedwith anti-IFNg antibody, and (D) SOCS12/2 IFNg2/2 mice. Cells were
proteins, it is also feasible that a regulatory role forstained with anti-B220 antibody and a mixture of anti-IgM and anti-
this protein in other cytokine signaling pathways is notIgD antibodies and analyzed by FACS.
evident in SOCS12/2 mice due to the compensatory ac-
tions of other SOCS proteins. In vitro studies have clearly
shown that SOCS1 and SOCS3 have overlapping activi-including IFNa, IFNb, IFNg, IL-6, LIF, OSM, thrombopoie-
ties, and both molecules are induced by and inhibit thetin, growth hormone, and stem cell factor (SCF). More-
actions of a similar spectrum of cytokines when overex-over, each of these cytokines is able to rapidly induce
pressed (Adams et al., 1998; Sakamoto et al., 1998; Songthe synthesis of SOCS1 mRNA (Endo et al., 1997; Starr
and Shuai, 1998; Ito et al., 1999). However, for regulationet al., 1997; Adams et al., 1998; Auernhammer et al.,
of IFNg signaling, SOCS1 appears to be considerably1998; Bjorbaek et al., 1998; Sakamoto et al., 1998; Song
more active than SOCS3 (Sakamoto et al., 1998; Songand Shuai, 1998; Ito et al., 1999; De Sepulveda et al.,
and Shuai, 1998). Consistent with these in vitro studies,1999).
the phenotype of SOCS12/2 mice reveals key roles forGiven the promiscuity of SOCS1 action in vitro, dis-
SOCS1 in regulating IFNg responses that cannot beease in mice lacking this protein might potentially have
compensated by SOCS3 in vivo. Whether SOCS3 alsobeen due to deregulation of signals from a multitude of
acts to regulate a unique set of cytokine signal transduc-cytokines. Remarkably, however, the full spectrum of
tion pathways and whether there are other pathwaysthe complex disease in SOCS12/2 mice, including liver
regulated by both SOCS1 and SOCS3 under physiologi-degeneration, hematopoietic infiltration of multiple tis-
cal conditions remains to be clarified.sues, and profound loss of T and B lymphocytes, can
be attributed to a failure to regulate signal transduction
by a single cytokine, IFNg. This implies that in contrast SOCS1 Balances the Beneficial and Potentially
Deleterious Actions of IFNgto its actions in vitro, under physiological conditions
SOCS1 has no indispensable role in the regulation of The potentially devastating actions of IFNg in vivo have
been well established in studies in which IFNg levelssignal transduction from the majority of cytokines that
utilize the JAK-STAT pathway. have been experimentally elevated (Gresser et al., 1981,
1987; Gresser, 1982), and these pathologies were faith-As the in vitro studies all involved overexpression of
SOCS1, it is possible that these approaches overesti- fully reproduced in mice lacking SOCS1. In addition,
inappropriate IFNg production and action is implicatedmated the breadth of SOCS action, simply because the
level of SOCS gene expression achieved experimentally in the pathogenesis of disease following certain infec-
tions. In a mouse transgenic model of hepatitis B, theis likely to be far higher than expression controlled by an
endogenous promoter. Moreover, ectopic expression destruction of liver cells and resultant morbidity appears
to be caused by excess endogenous IFNg (Ando et al.,may also be temporally inappropriate because physio-
logical transcription of SOCS genes appears to be de- 1993). In other models of infection, however, the actions
of IFNg are beneficial (Huang et al., 1993; Newport etpendent on exposure to cytokine, allowing SOCS pro-
teins to act in vivo only after signaling has commenced. al., 1996; Lu et al., 1998), and this action is also amplified
in mice lacking SOCS1. SOCS1-deficient macrophagesHowever, although it is clear that a lack of SOCS1 causes
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environment was monitored closely and tested continually for the
absence of bacterial organisms and a variety of viral pathogens.
Mice were genotyped by Southern blot analysis of genomic DNA
obtained from tail tips, as described (Starr et al., 1998). For analysis
of the SOCS1 gene, genomic DNA was digested with EcoRI and
filters were probed with a 1.5 kilobase pairs (kbp) EcoRI/HindIII
fragment of the mouse SOCS1 gene, which hybridizes to a 5.3 kbp
band for the wild-type allele and an 8.0 kbp fragment for the null
allele. For analysis of the IFNg gene, DNA was cut with BamHI and
filters were probed with a 450 bp PstI fragment of the mouse IFNg
cDNA that detects a fragment of 11.0 kbp for the wild-type allele
and 13.0 kbp for the null allele.
Neonatal mice were injected intraperitoneally twice weekly for up
to 3 weeks with 16 mg/kg of neutralizing rat anti-IFNg antibody (R4-
6A2; American Type Culture Collection, Manassas, VA), 200 mg/kg
of an ammonium sulfate±precipitated neutralizing polyclonal rabbit
anti-IL-6 antisera, as described (Liu et al., 1995), 16 mg/kg control
purified rat IgG antibody (Sigma Chemical Co., St. Louis, MO), or
200 mg/kg ammonium sulfate±precipitated preimmune rabbit sera
and were sacrificed when moribund or at the end of the experiment.
The efficacy of anti-IL-6 treatment was verified at the end of the
experiment by testing serum from injected mice for its capacity to
inhibit IL-6-induced differentiation of M1 cells. In a titration experi-
ment, a 1 in 100 dilution of serum from mice injected with the anti-
IL-6 but not control antibody was found to inhibit 60 ng/ml of IL-6.
In some experiments, 5-day-old mice were injected intraperitone-
ally with 50 ml of Semliki forest virus containing 100 times the virus
dose that kills 50% of fibroblasts in vitro. The mice were monitored
daily and sacrificed when moribund.
Figure 5. Absence of SOCS1 Renders Cells Hyperresponsive to
IFNg AssaysIFNg and Mice Hyperresistant to Semliki Forest Virus Infection
IFNg in serum was assayed using cytopathic effect reduction with
(A) Macrophages from the bone marrow of SOCS11/1 (filled sym-
mouse L929 cells as targets for Semliki forest virus challenge as
bols) and SOCS12/2 mice (open symbols) were stimulated with 100
described (Hertzog et al., 1991). A standard cytokine sandwich
ng/ml LPS and the indicated concentration of IFNg and infected
ELISA was also used to quantitate IFNg in mouse serum and organ-
with L. major. After 2 hr (circles) and 48 hr (squares), the percentage
conditioned media. IFNg-specific antibodies (R4-6A2 as the capture
of macrophages containing parasites was determined.
antibody, XMG1.2 for detection) were obtained from Pharmingen
(B) Mice generated by crossing SOCS11/2 mice were infected with
(San Diego, CA), and the assay was performed essentially as de-
Semliki forest virus at 5 days of age and monitored.
scribed by the manufacturer.
Hematological Analysis, Histology, and Immunohistochemistry
stimulated with IFNg killed intracellular parasites consid- Hematological analyses were performed as described (Starr et al.,
erably more efficiently than their wild-type counterparts, 1998; Metcalf et al., 1999). For histological examination, tissues were
fixed in 10% (v/v) formalin in phosphate-buffered saline (PBS) andand SOCS12/2 mice were more resistant than normal
sections were prepared and stained by standard techniques (Starrmice to Semliki forest virus infection. Clearly, the actions
et al., 1998). Tissue preparation for immunohistochemistry was car-of IFNg in vivo require exquisite control. The data pre-
ried out as described (Thomas et al., 1998), and sections were
sented here establish that SOCS1 is central to the bal- stained with a rat anti-mouse class I MHC antibody, 34-12S, and a
ance between the beneficial and potentially harmful ef- peroxidase-labeled secondary antibody. Sections were counter-
fects of IFNg. While the behavior of neonatal mice may stained with Giemsa (Ozato et al., 1982).
not necessarily predict the occurrence of similar re-
sponses to overstimulation by IFNg in humans, these Culture of Macrophages and Leishmanicidal Assays
To obtain bone marrow±derived macrophages, femoral bone mar-observations nevertheless raise the prospect that small
row cells collected in PBS were dispersed, centrifuged, and resus-molecule mimetics or antagonists of SOCS1 might prove
pended in 10 ml Dulbecco's modified Eagle's medium (DMEM) sup-clinically valuable in enhancing the actions of IFNg in
plemented with 100 ng/ml murine macrophage colony-stimulating
combating viral and parasitic infection or in dampening factor (M-CSF; Cetus Corporation, Emeryville, CA) and 10% (v/v)
its pathological side effects in other disease states. fetal bovine serum (FBS). After 3 days of culture in a humidified
incubator at 378C in 5% (v/v) CO2 in air, medium and nonadherent
cells containing an expanded precursor population were resus-Experimental Procedures
pended at 104 cells/ml and cultured for an additional 5 days in the
presence of M-CSF, after which a relatively pure and homogeneousGeneration and Maintenance of Mice and Injection
of Antibodies, Cytokine, and Virus population of adherent mature bone marrow macrophages were
present.SOCS12/2 mice were generated as described previously (Starr et
al., 1998) and maintained on a mixed 129/Sv and C57BL/6 genetic The cloned line of L. major LRC-L137 V 121 has been described in
detail (Handman, 1983). Promastigotes were grown in M199 mediumbackground. IFNg2/2 mice on an inbred C57BL/6 background
(C57BL/6-Ifngtm1Ts) were obtained from the Jackson Laboratories via with 10% FBS and were in the stationary phase of growth. Infection
of macrophages was carried out using a modification of a methodMonash University (Dalton et al., 1993). Mice were routinely housed
in clean but not specific pathogen-free conditions (SPF) at the Walter described previously (Proudfoot et al., 1995). Briefly, 5 3 104 bone
marrow±derived macrophages were transferred onto glass cov-and Eliza Hall Institute of Medical Research. To raise mice under
germ-free conditions, pups were delivered by cesarean section and erslips in 24-well trays, allowed to adhere for 24 hr, and stimulated
with 100 ng/ml LPS and various concentrations of IFNg. After 6 hrplaced with BALB/c foster mothers that had been maintained in
germ-free microisolators for several generations. The sterility of this of cytokine stimulation, cells were infected at a ratio of five parasites
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per cell for 2 hr at 378C. The free parasites were removed by vigorous expression and adrenocorticotropin secretion. Mol. Endocrinol. 12,
954±961.washing before incubation for a further 24 or 48 hr, after which cells
were stained with Giemsa. The percentage of macrophages infected Bach, E.A., Aguet, M., and Schreiber, R.D. (1997). The IFN gamma
with parasites was determined at each time point, with at least 400 receptor: a paradigm for cytokine receptor signaling. Annu. Rev.
cells per sample counted. Immunol. 15, 563±591.
Billiau, A. (1996). Interferon-gamma: biology and role in pathogene-
Northern Blots sis. Adv. Immunol. 62, 61±130.
Following sacrifice, organs were removed from neonatal wild-type Billiau, A., and Vandekerckhove, F. (1991). Cytokines and their inter-
and SOCS12/2 mice. PolyA1 mRNA was purified, and Northern blot actions with other inflammatory mediators in the pathogenesis of
hybridization was performed essentially as described (Alexander et sepsis and septic shock. Eur. J. Clin. Inv. 21, 559±573.
al., 1995). Probes used were as follows: a 1.1 kbp PstI fragment of
Bjorbaek, C., Elmquist, J.K., Frantz, J.D., Shoelson, S.E., and Flier,
the chicken glyceraldehyde 6-phosphate dehydrogenase (GAPDH)
J.S. (1998). Identification of SOCS-3 as a potential mediator of cen-
cDNA, a 2 kbp EcoRI fragment of the mouse IRF1 gene, and a 1.8 tral leptin resistance. Mol. Cell 1, 619±625.
kbp NcoI fragment of the mouse iNOS cDNA.
Boehm, U., Klamp, T., Groot, M., and Howard, J.C. (1997). Cellular
responses to interferon-gamma. Annu. Rev. Immunol. 15, 749±795.
Flow Cytometry
Dalton, D.K., Pitts-Meek, S., Keshav, S., Figari, I.S., Bradley, A., andSingle-cell suspensions of femoral bone marrow, thymocytes, and
Stewart, T.A. (1993). Multiple defects of immune cell function in micesplenocytes were prepared and erythrocytes were lysed by incuba-
with disrupted interferon-gamma genes. Science 259, 1739±1742.tion in 156 mM ammonium chloride (pH 7.3) at 378C for 3 min.
Darnell, J.E., Jr. (1997). STATs and gene regulation. Science 277,The cells were stained with a biotinylated or FITC-conjugated rat
1630±1635.monoclonal antibody specific for the cell surface markers of interest
Darnell, J.E., Jr., Kerr, I.M., and Stark, G.R. (1994). Jak-STAT path-(Class I MHC, CD4, CD8, surface IgM, surface IgD, B220, or Mac1),
ways and transcriptional activation in response to IFNs and otherfollowed where necessary by streptavidin-phycoerythrin and ana-
extracellular signaling proteins. Science 264, 1415±1421.lyzed by flow cytometry as described (Strasser et al., 1991).
De Maeyer, E., and De Maeyer-Guignard, S. (1998). Interferons. In
The Cytokine Handbook, A. Thomson, ed. (San Diego, CA: AcademicElectrophoretic Mobility Shift Assays
Press), pp. 491±516.Nuclei were extracted from the livers of unmanipulated SOCS12/2
De Sepulveda, P., Okkenhaug, K., La Rose, J., Hawley, R.G., Du-mice and control littermates or from mice 15 min after intraperitoneal
breuil, P., and Rottapel, R. (1999). Socs1 binds to multiple signalingadministration of 2 mg IFNg (Ruff-Jamison et al., 1993). Electropho-
proteins and suppresses Steel factor dependent proliferation.retic mobility shift assays (EMSA) were performed on 1±2 mg of
EMBO J. 18, 904±915.nuclear protein using the m67 oligonucleotide probe as described
(Novak et al., 1995). Durbin, J.E., Hackenmiller, R., Simon, M.C., and Levy, D.E. (1996).
Targeted disruption of the mouse Stat1 gene results in compromised
innate immunity to viral disease. Cell 84, 443±450.Acknowledgments
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